Fenofibrate
- Generic Name
- Fenofibrate
- Brand Names
- Antara, Cholib, Fenoglide, Fenomax, Lipidil Supra, Lipofen, Tricor, Triglide
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21ClO4
- CAS Number
- 49562-28-9
- Unique Ingredient Identifier
- U202363UOS
- Background
Fenofibrate is a fibric acid derivative like clofibrate and gemfibrozil. Fenofibrate is used to treat primary hypercholesterolemia, mixed dyslipidemia, severe hypertriglyceridemia.
Fenofibrate was granted FDA approval on 31 December 1993.
- Indication
Fenofibrate is indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C, Triglycerides, and Apo B, and to increase HDL-C adults with primary hypercholesterolemia or mixed dyslipidemia. Fenofibrate is also indicated to treat adults with severe hypertriglyceridemia.
- Associated Conditions
- Mixed Dyslipidemias, Primary Hypercholesterolemia, Severe Hypertriglyceridemia (sHTG), Severe Fredrickson Type IV Hypertriglyceridemia, Severe Fredrickson Type V Hypertriglyceridemia
- Associated Therapies
- -
LXRA Gene Polymorphisms and Response to Fenofibrate
- Conditions
- Interventions
- First Posted Date
- 2008-03-27
- Last Posted Date
- 2012-06-01
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 11
- Registration Number
- NCT00644592
- Locations
- 🇺🇸
University of Florida College of Pharmacy, Center for Pharmacogenomics, Gainesville, Florida, United States
Effect of a PPAR-Alpha Agonist on the Age Related Changes in Myocardial Metabolism and Mechanical Function
- First Posted Date
- 2008-03-03
- Last Posted Date
- 2009-02-19
- Lead Sponsor
- National Institute on Aging (NIA)
- Target Recruit Count
- 60
- Registration Number
- NCT00627653
- Locations
- 🇺🇸
Washington University School of Medicine, St Louis, Missouri, United States
Fenofibrate and Pharmacogenetic Impact in Dyslipidemia
- First Posted Date
- 2008-02-13
- Last Posted Date
- 2020-01-13
- Lead Sponsor
- University of Minnesota
- Target Recruit Count
- 56
- Registration Number
- NCT00613613
- Locations
- 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
Effect of Fenofibrate on Endothelial Function and High-density Lipoproteins (HDL)in Patients With Coronary Heart Disease
- Conditions
- Interventions
- First Posted Date
- 2007-11-02
- Last Posted Date
- 2011-03-10
- Lead Sponsor
- National Heart Institute, Mexico
- Target Recruit Count
- 76
- Registration Number
- NCT00552747
- Locations
- 🇲🇽
Endocrinology Department National Institute of Cardiology Ignacio Chavez, Mexico City, Mexico
Evaluating How the Treatments in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Affect Diabetic Retinopathy (The ACCORD Eye Study)
- First Posted Date
- 2007-10-10
- Last Posted Date
- 2018-07-24
- Target Recruit Count
- 3472
- Registration Number
- NCT00542178
- Locations
- 🇺🇸
Veterans Affairs, Memphis, Tennessee, United States
🇺🇸Columbia University, New York, New York, United States
🇺🇸The Berman Center for Clinical Research, Minneapolis, Minnesota, United States
Study of Atorvastatin/Fenofibrate (LCP-AtorFen) Combination Therapy in Dyslipidemia
- Conditions
- Interventions
- First Posted Date
- 2007-07-20
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- Veloxis Pharmaceuticals
- Target Recruit Count
- 220
- Registration Number
- NCT00504829
- Locations
- 🇺🇸
Radiant Research, 515 N State Street, Suite 2700, Chicago, Illinois, United States
Effect of a Fibrate and a Statin on Endothelial Dysfunction
- Conditions
- Interventions
- First Posted Date
- 2007-06-26
- Last Posted Date
- 2012-10-24
- Lead Sponsor
- Boston University
- Target Recruit Count
- 28
- Registration Number
- NCT00491400
- Locations
- 🇺🇸
Boston Medical Center, Boston, Massachusetts, United States
Tissue Lipids and Insulin Resistance
- Conditions
- First Posted Date
- 2007-06-06
- Last Posted Date
- 2015-03-04
- Lead Sponsor
- University of Arkansas
- Registration Number
- NCT00483210
A Study to Evaluate Daily Pravastatin, Fenofibrate or Pravafen in the Treatment of Combined Hyperlipidemia
- Conditions
- Interventions
- First Posted Date
- 2007-04-12
- Last Posted Date
- 2018-04-24
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 481
- Registration Number
- NCT00459745
- Locations
- 🇺🇸
East-West Medical Research Institute, Honolulu, Hawaii, United States
🇺🇸Welborn Clinic Gateway, Newburgh, Indiana, United States
🇺🇸Memorial Research Medical Clinic, Long Beach, California, United States
Effects of Fenofibrate on the Safety, Toleration and Efficacy Biomarkers of CP-742,033
- Conditions
- First Posted Date
- 2006-09-14
- Last Posted Date
- 2015-04-22
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00376285
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.